AVITA Medical Inc. (RCEL)
undefined
undefined%
At close: undefined
12.21
0.08%
After-hours Dec 13, 2024, 04:00 PM EST

Company Description

AVITA Medical Inc. operates as a commercial-stage regenerative tissue company in the United States, Australia, and the United Kingdom.

It offers regenerative products to address unmet medical needs in burn injuries, trauma injuries, chronic wounds, and dermatological and aesthetics indications, including vitiligo.

The company's patented and proprietary platform technology provides treatment solutions derived from the regenerative properties of a patient's own skin.

Its lead product is RECELL System, a device that enables healthcare professionals to produce a suspension of Spray-On Skin cells using a small sample of the patient's own skin for use in the treatment of acute thermal burns in patients eighteen years and older.

The company has a research collaboration with the University of Colorado School of Medicine to establish pre-clinical proof-of-concept for a spray-on treatment of genetically corrected cells; and a research collaboration with Houston Methodist Research Institute to explore molecular reversal of cellular aging through a novel cell suspension delivery system.

The company was formerly known as AVITA Therapeutics, Inc. and changed its name to AVITA Medical Inc. in December 2020.

AVITA Medical Inc. was incorporated in 2000 and is based in Valencia, California.

AVITA Medical Inc.
AVITA Medical Inc. logo
Country United States
IPO Date May 14, 2012
Industry Medical - Devices
Sector Healthcare
Employees 207
CEO James M. Corbett

Contact Details

Address:
28159 Avenue Stanford
Valencia, California
United States
Website https://www.avitamedical.com

Stock Details

Ticker Symbol RCEL
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001762303
CUSIP Number 05380C102
ISIN Number US05380C1027
Employer ID 20-2578762
SIC Code 3841

Key Executives

Name Position
James M. Corbett Chief Executive Officer, President & Executive Director
David O'Toole Chief Financial Officer
David Fencil Senior Vice President of Global Operations
Debbie Garner Senior Vice President of Global Marketing & Strategy
Dr. Katie Bush Ph.D. Senior Vice President of Scientific & Medical Affairs
Dr. Niraj Doshi J.D., P.M.P., Ph.D. Senior Vice President of Product Development & Program Management
Jessica Ekeberg Investor Relations Executive
Nicole Linda Kelsey Chief Legal & Compliance Officer and Corporate Secretary
Rob Hall Senior Vice President of Human Resources
Ron Lagerquist Senior Vice President of Quality Assurance & Regulatory Affairs

Latest SEC Filings

Date Type Title
Dec 05, 2024 4 Filing
Nov 07, 2024 10-Q Quarterly Report
Nov 07, 2024 8-K Current Report
Aug 20, 2024 4 Filing
Aug 08, 2024 S-8 Filing
Aug 08, 2024 10-Q Quarterly Report
Aug 08, 2024 8-K Current Report
Jul 31, 2024 8-K Current Report
Jul 03, 2024 3 Filing
Jul 01, 2024 8-K Current Report